RO23-6240, a new orally absorbed quinolone: in vitro comparison with other broad-spectrum oral antimicrobial agents and imipenem.
A total of 626 clinical isolates were tested for their susceptibility to RO23-6240 and other broad-spectrum antimicrobial agents. RO23-6240 showed good activity against strains of Enterobacteriaceae, Acinetobacter, and P. aeruginosa. RO23-6240 MIC90s ranged from 0.032 to 4 micrograms/ml for these strains. RO23-6240 also showed good activity against staphylococci, both methicillin-susceptible and -resistant strains. The activity in vitro of RO23-6240 was comparable with that of norfloxacin and ofloxacin, and more active than imipenem, trimethoprim-sulfamethoxazole, cefaclor, and amoxycillin/clavulanate potassium. As with the other quinolones tested, increases in inoculum size produced moderate increases in the MICs and MBCs of RO23-6240.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D016576:Fleroxacin; D015378:Imipenem; D008826:Microbial Sensitivity Tests; D013845:Thienamycins / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D002939:Ciprofloxacin; D015378:Imipenem; D016576:Fleroxacin